At ASCO 2019, results were presented from the phase II EV-201 trial, which evaluated antibody drug conjugate (ADC) enfortumab vedotin in relapsed patients with locally advanced or metastatic bladder cancer.
The data presented were from Cohort 1 of the trial, which evaluated enfortumab in relapsed patients who had been treated with a platinum and a checkpoint inhibitor. Kantar’s Len Kusdra reviews the study in the video below.
